Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Ukraine

- PMLiVE

Janssen’s Talvey granted FDA accelerated approval for difficult-to-treat blood cancer

The therapy showed an overall response rate of more than 70% in a broad range of patients

- PMLiVE

World Health Organization classifies EG.5 as a COVID-19 ‘variant of interest’

The strain accounted for over 17% of COVID-19 cases between 17 and 23 July

- PMLiVE

JCVI announces advice for autumn COVID-19 booster vaccine eligibility

The Committee has advised offering the booster to those at high risk of serious disease

- PMLiVE

MHRA authorises HIPRA Human Health’s COVID-19 vaccine for use in UK

Bimervax is the ninth COVID-19 vaccine to be authorised by the UK medicines regulator

- PMLiVE

US NIH launches mid-stage long COVID trials to evaluate at least four treatments

One trial will test a longer dosing regimen of Pfizer’s antiviral COVID-19 drug Paxlovid

Can Cinderella save us?

New study finds vaccines could avert 500,000 antimicrobial resistance deaths each year

AMR has been declared by WHO as one of the top ten threats to global public health

- PMLiVE

World Health Organization publishes updated essential medicines list

Three medicines that can delay or slow MS disease progression have been included in the EML

- PMLiVE

Janssen receives positive CHMP opinion for Talvey in multiple myeloma

More than 50,900 people in Europe were diagnosed with multiple myeloma in 2020

- PMLiVE

Johnson & Johnson sues US government over Medicare drug price negotiation programme

The IRA allows Medicare to negotiate lower prices for a selected group of medicines

- PMLiVE

Gilead’s COVID-19 treatment approved by FDA for patients with severe renal impairment

Use of Veklury among this patient population has previously been limited

- PMLiVE

Janssen signs $2.5bn deal with Nanobiotix for late-stage radiotherapy enhancer

The agreement marks a significant boost to the Johnson & Johnson unit’s oncology pipeline

- PMLiVE

Novavax’s COVID-19 vaccine granted full marketing authorisation in EU

The EC’s decision was supported by positive results from a phase 3 trial evaluating Nuvaxovid

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links